Eyepoint Pharmac Stock Price, News & Analysis

EyePoint Pharmaceuticals (EYPT) reported estimated net product revenues for Q3 2020 between $5.5 and $5.9 million, a significant increase from $3.7 million in Q2 2020, as healthcare facilities resumed operations after COVID-19 closures.

Driving this growth was customer demand for YUTIQ and DEXYCU, with estimated revenues of $3.4-$3.5 million and $2.1-$2.4 million respectively. Demand for YUTIQ units increased to 450, while DEXYCU saw a rise to 4,700 units in Q3 2020.

EyePoint Pharmaceuticals (NASDAQ:EYPT) will have CEO Nancy Lurker present at two virtual conferences this September. The Cantor Virtual Healthcare Conference is scheduled for September 15 at 4:40 PM Eastern Time, followed by the H.C. Wainwright 22nd Annual Global Investment Conference on September 16 at 2:00 PM Eastern Time. A live webcast and replay will be accessible on their Investors page for 90 days. EyePoint specializes in innovative ophthalmic products, with commercial offerings including DEXYCU® and YUTIQ®, as well as pipeline developments using their Durasert® technology.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has entered a purchase and marketing agreement with Vantage Outsourcing for its ophthalmic product DEXYCU®, enabling broader access in over 25 states. This collaboration aims to integrate DEXYCU into surgical protocols for treating ocular inflammation related to cataract surgery. President Nancy Lurker emphasizes the partnership's potential for expanding their reach within the cataract surgery market. Vantage Outsourcing's services will enhance the postoperative experience for patients by providing a long-lasting anti-inflammatory treatment.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has expanded its exclusive licensing agreements with Ocumension Therapeutics for the commercialization of YUTIQ® and DEXYCU® in Asian markets. Ocumension will pay EyePoint $9.5 million, which covers prior milestone payments for regulatory and commercial sales. This partnership aims to enhance the availability of these therapies in South Korea and Southeast Asia, addressing significant unmet medical needs in ocular diseases. The financial influx will support ongoing clinical developments, including EYP-1901, a potential six-month treatment for wet age-related macular degeneration.

EyePoint Pharmaceuticals (NASDAQ: EYPT) presented data supporting the efficacy of YUTIQ® at the ASRS Virtual Annual Meeting. YUTIQ is a fluocinolone acetonide intravitreal implant for treating chronic, non-infectious uveitis affecting the posterior segment of the eye. The Phase 3 trial involved 129 patients and highlighted a lower recurrence rate of uveitis with YUTIQ compared to sham treatment. Key findings included a 48% reduction in macular edema for YUTIQ patients and improved visual acuity results. YUTIQ is indicated for long-term treatment, providing benefits during the COVID-19 pandemic.

EyePoint Pharmaceuticals (NASDAQ: EYPT) appointed Dr. Jay S. Duker as Chief Strategic Scientific Officer to lead the development of EYP-1901, targeted at wet age-related macular degeneration. Dr. Duker, a renowned retina specialist with over 30 years of experience, will focus on advancing research and pipeline expansion while continuing to practice medicine. He steps down from the Board of Directors to take on this part-time role. The company granted him stock options for 250,000 shares as part of the inducement for his appointment.

EyePoint Pharmaceuticals (NASDAQ:EYPT) announced that CEO Nancy Lurker will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 8:30 AM ET. The event will be streamed live and an archived replay will be available on the company's website for 90 days. EyePoint is focused on innovative ophthalmic products addressing unmet medical needs, with two commercial products: DEXYCU and YUTIQ. Their pipeline includes EYP-1901, a VEGF inhibitor aimed at treating various serious eye disorders. For more information, visit www.eyepointpharma.com.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced positive retrospective case study results for DEXYCU® (dexamethasone intraocular suspension) 9% aimed at treating post-operative inflammation after ocular surgeries. Presented at ASCRS 2020, interim data included significant improvements in inflammation metrics among patients. With a projected enrollment of 600 patients, the study confirms DEXYCU's efficacy over traditional steroid drops, enhancing patient adherence and minimizing hospital visits amid pandemic concerns. The findings bolster the perceived advantages of DEXYCU in clinical settings.

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported total revenues of $7.5 million for Q1 2020, up from $2.0 million in Q1 2019. Net product revenues reached $4.7 million, driven primarily by $3.6 million from YUTIQ and $1.1 million from DEXYCU. Operating expenses increased to $18.9 million, leading to a net loss of $13.2 million or $0.11 per share. The company has initiated GLP toxicology studies for its EYP-1901 treatment and expects to file an IND application later this year. Cash reserves stand at $26.3 million, supporting operations amid COVID-19 challenges.